What Happened

Cognition Therapeutics received FDA agreement that DLB psychosis could be an approvable outcome and alignment on key aspects of a Phase 3 trial design for zervimesine (CT1812). The pivotal study will randomize patients to 100mg daily zervimesine or placebo for 9 months, using NPI as a novel primary endpoint.

Who Is Affected

Cognition's commercial and clinical teams must now execute the mid-2027 registrational program. Biopharma vendors supporting CNS trials and commercial launch prep should prioritize engagement. Payers and clinicians treating DLB patients (currently reliant on off-label antipsychotics) are key stakeholders.

Market Impact

• $300M shelf registration provides funding flexibility but potential dilution risk
• Stock swung from -33% to +7.2% post-announcement
• 6.2x average trading volume indicates high institutional interest
• No sector-wide rotation observed - stock-specific movement

What to Watch

Phase 3 trial initiation in mid-2027 and AAIC presentation of Phase 2 NPI data in July 2026. Monitor for shelf utilization and commercial hiring signals as Cognition prepares for a potential first-in-class DLB psychosis approval.